
News|Articles|February 13, 2019
Gamifant for Primary Hemophagocytic Lymphohistiocytosis
Author(s)Drew Boxler
Advertisement
Gamifant (emapalumab-lzsg, Sobi)
Indications: patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
Dosage: 1 mg/kg as an intravenous infusion over 1 hour twice per week; Administer dexamethasone concomitantly with GAMIFANT.
Contraindications:None
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
The Emergence of CGRP-Targeted Therapies is Transforming Migraine Care | NCPA 2025
2
Pharmacists Experience Challenges in Credentialing, Billing for Services | NCPA 2025
3
FDA Approves Oral Semaglutide for Risk of MACE for Patients With Diabetes
4
FDA Approves Enflonsia for the Prevention of RSV Lower Respiratory Tract Disease in Infants
5